Donor-derived metastatic melanoma in a liver transplant recipient established by DNA fingerprinting

Muhammad Bilal, James D. Eason, Kanak Das, Pamela B. Sylvestre, Amanda G. Dean, Jason M. Vanatta

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Metastatic melanoma is a donor-derived malignancy that has rarely been reported in liver allograft recipients. We present a case of a transmitted donorderived melanoma to a liver allograft recipient in whom the diagnosis was established by polymerase chain reaction-based DNA fingerprinting. A 52-year-old African-American man underwent a successful orthotropic liver transplant for alcoholinduced cirrhosis. One year after the orthotropic liver transplant, he presented at our institution with diffuse abdominal pain, and a computed tomography scan of the abdomen and chest showed innumerable masses diffusely involving the liver and multiple subcutaneous nodules in the abdominal and chest wall. A liver biopsy confirmed the diagnosis of metastatic melanoma. The origin of melanoma was traced to the donor by DNA fingerprinting of the native liver, the donor liver, and the donor gallbladder. Chemotherapy was initiated with temozolomide (75 mg/m2 daily) and thalidomide (50 mg daily), to which he responded within 8 weeks with radiologic improvement in metastatic lesions. Tacrolimus was switched to sirolimus because of renal insufficiency as well as reported effectiveness against melanoma. Our patient survived for 9 months after the diagnosis of metastatic melanoma. He ultimately died of brain metastases. Donor-derived metastatic melanoma is a rare cancer with the highest transmission and mortality rates, which requires better recognition. Prompt diagnosis of donor-derived melanoma is critical and can be achieved reliably with polymerase chain reaction-based DNA analysis. Management options after diagnosis include de-escalation of immunosuppression, with or without urgent organ removal or retransplant. The roles of chemotherapy, immunotherapy, and radiotherapy require further study.

Original languageEnglish (US)
Pages (from-to)458-463
Number of pages6
JournalExperimental and Clinical Transplantation
Volume11
Issue number5
DOIs
StatePublished - Oct 1 2013

Fingerprint

DNA Fingerprinting
Melanoma
Tissue Donors
Liver
temozolomide
Allografts
Transplants
Drug Therapy
Polymerase Chain Reaction
Thalidomide
Transplant Recipients
Abdominal Wall
Thoracic Wall
Tacrolimus
Sirolimus
Gallbladder
African Americans
Abdomen
Immunotherapy
Immunosuppression

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Donor-derived metastatic melanoma in a liver transplant recipient established by DNA fingerprinting. / Bilal, Muhammad; Eason, James D.; Das, Kanak; Sylvestre, Pamela B.; Dean, Amanda G.; Vanatta, Jason M.

In: Experimental and Clinical Transplantation, Vol. 11, No. 5, 01.10.2013, p. 458-463.

Research output: Contribution to journalArticle

Bilal, Muhammad ; Eason, James D. ; Das, Kanak ; Sylvestre, Pamela B. ; Dean, Amanda G. ; Vanatta, Jason M. / Donor-derived metastatic melanoma in a liver transplant recipient established by DNA fingerprinting. In: Experimental and Clinical Transplantation. 2013 ; Vol. 11, No. 5. pp. 458-463.
@article{1e7586ba7aff42e785577d35ca3ced9c,
title = "Donor-derived metastatic melanoma in a liver transplant recipient established by DNA fingerprinting",
abstract = "Metastatic melanoma is a donor-derived malignancy that has rarely been reported in liver allograft recipients. We present a case of a transmitted donorderived melanoma to a liver allograft recipient in whom the diagnosis was established by polymerase chain reaction-based DNA fingerprinting. A 52-year-old African-American man underwent a successful orthotropic liver transplant for alcoholinduced cirrhosis. One year after the orthotropic liver transplant, he presented at our institution with diffuse abdominal pain, and a computed tomography scan of the abdomen and chest showed innumerable masses diffusely involving the liver and multiple subcutaneous nodules in the abdominal and chest wall. A liver biopsy confirmed the diagnosis of metastatic melanoma. The origin of melanoma was traced to the donor by DNA fingerprinting of the native liver, the donor liver, and the donor gallbladder. Chemotherapy was initiated with temozolomide (75 mg/m2 daily) and thalidomide (50 mg daily), to which he responded within 8 weeks with radiologic improvement in metastatic lesions. Tacrolimus was switched to sirolimus because of renal insufficiency as well as reported effectiveness against melanoma. Our patient survived for 9 months after the diagnosis of metastatic melanoma. He ultimately died of brain metastases. Donor-derived metastatic melanoma is a rare cancer with the highest transmission and mortality rates, which requires better recognition. Prompt diagnosis of donor-derived melanoma is critical and can be achieved reliably with polymerase chain reaction-based DNA analysis. Management options after diagnosis include de-escalation of immunosuppression, with or without urgent organ removal or retransplant. The roles of chemotherapy, immunotherapy, and radiotherapy require further study.",
author = "Muhammad Bilal and Eason, {James D.} and Kanak Das and Sylvestre, {Pamela B.} and Dean, {Amanda G.} and Vanatta, {Jason M.}",
year = "2013",
month = "10",
day = "1",
doi = "10.6002/ect.2012.0243",
language = "English (US)",
volume = "11",
pages = "458--463",
journal = "Experimental and Clinical Transplantation",
issn = "1304-0855",
publisher = "Baskent University",
number = "5",

}

TY - JOUR

T1 - Donor-derived metastatic melanoma in a liver transplant recipient established by DNA fingerprinting

AU - Bilal, Muhammad

AU - Eason, James D.

AU - Das, Kanak

AU - Sylvestre, Pamela B.

AU - Dean, Amanda G.

AU - Vanatta, Jason M.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Metastatic melanoma is a donor-derived malignancy that has rarely been reported in liver allograft recipients. We present a case of a transmitted donorderived melanoma to a liver allograft recipient in whom the diagnosis was established by polymerase chain reaction-based DNA fingerprinting. A 52-year-old African-American man underwent a successful orthotropic liver transplant for alcoholinduced cirrhosis. One year after the orthotropic liver transplant, he presented at our institution with diffuse abdominal pain, and a computed tomography scan of the abdomen and chest showed innumerable masses diffusely involving the liver and multiple subcutaneous nodules in the abdominal and chest wall. A liver biopsy confirmed the diagnosis of metastatic melanoma. The origin of melanoma was traced to the donor by DNA fingerprinting of the native liver, the donor liver, and the donor gallbladder. Chemotherapy was initiated with temozolomide (75 mg/m2 daily) and thalidomide (50 mg daily), to which he responded within 8 weeks with radiologic improvement in metastatic lesions. Tacrolimus was switched to sirolimus because of renal insufficiency as well as reported effectiveness against melanoma. Our patient survived for 9 months after the diagnosis of metastatic melanoma. He ultimately died of brain metastases. Donor-derived metastatic melanoma is a rare cancer with the highest transmission and mortality rates, which requires better recognition. Prompt diagnosis of donor-derived melanoma is critical and can be achieved reliably with polymerase chain reaction-based DNA analysis. Management options after diagnosis include de-escalation of immunosuppression, with or without urgent organ removal or retransplant. The roles of chemotherapy, immunotherapy, and radiotherapy require further study.

AB - Metastatic melanoma is a donor-derived malignancy that has rarely been reported in liver allograft recipients. We present a case of a transmitted donorderived melanoma to a liver allograft recipient in whom the diagnosis was established by polymerase chain reaction-based DNA fingerprinting. A 52-year-old African-American man underwent a successful orthotropic liver transplant for alcoholinduced cirrhosis. One year after the orthotropic liver transplant, he presented at our institution with diffuse abdominal pain, and a computed tomography scan of the abdomen and chest showed innumerable masses diffusely involving the liver and multiple subcutaneous nodules in the abdominal and chest wall. A liver biopsy confirmed the diagnosis of metastatic melanoma. The origin of melanoma was traced to the donor by DNA fingerprinting of the native liver, the donor liver, and the donor gallbladder. Chemotherapy was initiated with temozolomide (75 mg/m2 daily) and thalidomide (50 mg daily), to which he responded within 8 weeks with radiologic improvement in metastatic lesions. Tacrolimus was switched to sirolimus because of renal insufficiency as well as reported effectiveness against melanoma. Our patient survived for 9 months after the diagnosis of metastatic melanoma. He ultimately died of brain metastases. Donor-derived metastatic melanoma is a rare cancer with the highest transmission and mortality rates, which requires better recognition. Prompt diagnosis of donor-derived melanoma is critical and can be achieved reliably with polymerase chain reaction-based DNA analysis. Management options after diagnosis include de-escalation of immunosuppression, with or without urgent organ removal or retransplant. The roles of chemotherapy, immunotherapy, and radiotherapy require further study.

UR - http://www.scopus.com/inward/record.url?scp=84885652016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885652016&partnerID=8YFLogxK

U2 - 10.6002/ect.2012.0243

DO - 10.6002/ect.2012.0243

M3 - Article

VL - 11

SP - 458

EP - 463

JO - Experimental and Clinical Transplantation

JF - Experimental and Clinical Transplantation

SN - 1304-0855

IS - 5

ER -